GlassScriptPhysician profile
Ridhi Gupta
NPI 1780953752
$5,500.29
in general payments reported to CMS, 2019-2025
24 companies · $4,929 in 2025
The $4,929 reported for 2025 was more than what 82% of Hematology & Oncology providers received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $91.08 · 2020: $27.26 · 2021: $60.73 · 2022: $208 · 2023: $19.90 · 2024: $165 · 2025: $4,929.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $3,760 · Food and Beverage: $1,254 · Education: $99.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $3,760.00 |
| Food and Beverage | $1,254.20 |
| Education | $99.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Legend Biotech USA INC. | $2,402.78 | 2025 | Carvykti |
| Janssen Biotech, INC. | $1,898.04 | 2025 | Talvey, Tecvayli, Darzalex |
| Kite Pharma, INC. | $234.20 | 2025 | Yescarta |
| Karyopharm Therapeutics INC. | $140.79 | 2025 | Xpovio |
| Incyte Corporation | $134.96 | 2021-2024 | |
| Astrazeneca Pharmaceuticals LP | $128.38 | 2020-2025 | Enhertu |
| Pfizer INC. | $104.53 | 2019-2025 | |
| Glaxosmithkline, LLC. | $74.80 | 2022-2025 | Ojjaara, Blenrep |
| E.R. Squibb & Sons, L.L.C. | $41.24 | 2019-2022 | |
| Genentech USA, INC. | $33.94 | 2019 | |
| Novartis Pharmaceuticals Corporation | $32.31 | 2025 | |
| Celgene Corporation | $29.15 | 2024 | Reblozyl |
| Cti Biopharma Corp. | $29.11 | 2022 | |
| Sanofi-Aventis U.S. LLC | $26.23 | 2025 | |
| Stemline Therapeutics INC. | $25.00 | 2025 | Elzonris |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Emd Serono, INC. | $23.12 | 2022 | |
| Abbvie INC. | $22.83 | 2025 | |
| Tg Therapeutics, INC. | $22.34 | 2022 | |
| Morphosys, US INC. | $21.24 | 2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $20.36 | 2022 | |
| Sobi, INC | $19.82 | 2024 | |
| Progenics Pharmaceuticals, INC. | $18.36 | 2022 | |
| Genzyme Corporation | $16.76 | 2024 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ridhi Gupta listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.